MEDIQON Group AG AI Stock Analysis
Want to see DE:CHG full AI Analyst Report?
MEDIQON Group AG (CHG) AI Stock Analysis
MEDIQON Group AG
(XETRA:CHG)
The score is dominated by deteriorating fundamentals: MEDIQON has never been profitable, and FY2025 saw negative gross profit, a -€50M EBIT, and a net loss widening to -€29.6M, while total debt tripled to €247.9M against €224M of equity. Positive operating (€8.7M) and free cash flow (€7.0M) provide some reassurance that the acquired businesses generate cash, but the amounts are small relative to the debt load and are trending lower. Technicals add further caution, with the stock below its 20- and 50-day averages and a negative MACD, though deeply oversold RSI and Stochastic readings and price holding above the 100- and 200-day averages leave room for a near-term rebound. Valuation offers no support given negative earnings and no dividend. Overall, this is a high-risk, acquisition-driven growth story that has yet to demonstrate sustainable profitability.
MEDIQON Group AG (CHG) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 1.01B
- Dividend Yield
- ―
- Average Volume (3M)
- 26.07K
- Price to Earnings (P/E)
- -29.1
- Beta (1Y)
- 0.22
- Revenue Growth
- 63.32%
- EPS Growth
- -47.16%
- Country
- Germany
- Employees
- 1,300
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Software - Application
MEDIQON Group AG Business Overview & Revenue Model
Company Description
CHAPTERS Group AG, headquartered in Hamburg, Germany, was established in 1998 and rebranded from MEDIQON Group AG in July 2023. The company delivers a broad spectrum of software solutions across the DACH region, catering to numerous industries and ap...
MEDIQON Group AG Financial Statement Overview
Summary
Financials are weak overall. Revenue has scaled impressively to €180.8M (+37.4% YoY) via an acquisition-led roll-up strategy, but the company has never reported positive net income, and FY2025 deteriorated sharply: gross profit turned negative (-€12.2M), EBITDA swung to -€2.4M, EBIT fell to -€50M, and the net loss widened to -€29.6M. The balance sheet is a mixed picture — equity is stable near €224M and assets total €665M, but total debt more than tripled to €247.9M, lifting debt-to-equity to roughly 1.11x. Cash flow is the relative bright spot, with operating cash flow of €8.7M and free cash flow of €7.0M, though both declined year-over-year and the ~3.9% FCF margin is thin relative to the debt load.
Income Statement
25NegativeBalance Sheet
40NegativeCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2021 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 214.95M | 180.80M | 110.67M | 70.77M | 28.66M | 42.07M |
| Gross Profit | -5.09M | -12.21M | 47.02M | 8.38M | 12.26M | 6.84M |
| EBITDA | 16.44M | -2.40M | 16.35M | 16.14M | 7.16M | 4.82M |
| Net Income | -34.72M | -29.65M | -11.47M | -4.08M | -2.27M | -5.88M |
Balance Sheet | ||||||
| Total Assets | 671.97M | 665.02M | 353.74M | 223.95M | 103.55M | 169.28M |
| Cash, Cash Equivalents and Short-Term Investments | 115.41M | 106.74M | 58.51M | 50.84M | 11.09M | 26.28M |
| Total Debt | 265.58M | 247.94M | 73.60M | 69.35M | 51.70M | 62.09M |
| Total Liabilities | 389.28M | 351.45M | 128.75M | 99.87M | 61.71M | 77.11M |
| Stockholders Equity | 203.11M | 223.87M | 224.99M | 126.06M | 42.57M | 93.76M |
Cash Flow | ||||||
| Free Cash Flow | 6.92M | 7.02M | 6.96M | 3.81M | 1.15M | 3.67M |
| Operating Cash Flow | 8.91M | 8.68M | 11.47M | 7.37M | 2.87M | 5.69M |
| Investing Cash Flow | -49.57M | -103.89M | -98.82M | -36.34M | -47.40M | -53.21M |
| Financing Cash Flow | 86.39M | 134.24M | 89.00M | 48.15M | 47.06M | 58.78M |
MEDIQON Group AG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:CHG, the sentiment is Negative. The current price of 43.50 is below the 20-day moving average (MA) of 46.05, below the 50-day MA of 43.97, and above the 200-day MA of 37.22, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 41.24 is Neutral, neither overbought nor oversold. The STOCH value of 15.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:CHG.
MEDIQON Group AG Peers Comparison
Overall Rating
DE:OBS78Outperform
DE:ADN168Neutral
DE:BC860Neutral
DE:A1OS50Neutral
DE:CHG39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | EUR 44.32M | 11.70 | 10.52% | 2.14% | 0.88% | 9.19% | |
| 68Neutral | EUR 534.01M | 20.55 | 13.35% | 0.95% | 12.62% | 91.34% | |
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| 60Neutral | EUR 4.07B | 16.49 | 12.00% | 2.17% | 7.74% | 14.82% | |
| 50Neutral | EUR 386.60M | -38.61 | -8.99% | 1.55% | -1.94% | -161.38% | |
| 39Underperform | EUR 1.08B | -29.07 | -16.26% | ― | 63.32% | -47.16% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:CHG | MEDIQON Group AG | 43.50 | 7.60 | 21.17% | |
| DE:ADN1 | adesso AG | 76.70 | -14.90 | -16.27% | |
| DE:A1OS | All For One Group Se | 78.00 | 40.51 | 108.07% | |
| DE:BC8 | Bechtle Aktiengesellschaft | 32.26 | -5.46 | -14.48% | |
| DE:OBS | ORBIS AG | 4.76 | -1.12 | -19.05% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026
